(+)-Kavain
Product Sizes
10 mg
£ POA
HY-B1671-10MG
5 mg
£ POA
HY-B1671-5MG
10mM/1mL
£ POA
HY-B1671-10MM
25 mg
£ POA
HY-B1671-25MG
50 mg
£ POA
HY-B1671-50MG
100 mg
£ POA
HY-B1671-100MG
About this Product
- SKU:
- HY-B1671
- Application:
- Electron Microscopy
- CAS Number:
- 500-64-1
- Extra Details:
- (+)-Kavain; a main kavalactone that can be extracted from Piper methysticum; has anticonvulsive properties; attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels[1]. (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy[2]. (+)-Kavain is used as a treatment for inflammatory diseases; its anti-inflammatory action has been widely studied[4].
- Molecular Weight:
- 230.26
- Purity:
- 99.98
- References:
- [1]Bradić I, et al. [Hirschsprung's disease -- therapy and results]. Acta Chir Iugosl. 1975;22(2):183-95.|[2]Chua HC, et al. Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism. PLoS One. 2016 Jun 22;11(6):e0157700.|[3]G. Boonen, et al. In vivo Effects of the Kavapyrones (+)-Dihydromethysticin and (±)-Kavain on Dopamine, 3,4-Dihydroxyphenylacetic Acid, Serotonin and 5-Hydroxyindoleacetic Acid Levels in Striatal and Cortical Brain Regions. Planta Medica 64 (1998) 507-510.|[4]Tang X, et al. Kavain Inhibition of LPS-Induced TNF-α via ERK/LITAF. Toxicol Res (Camb). 2016 Jan 1;5(1):188-196.
- Research Area:
- Metabolic Disease;Neurological Disease
- Shipping Conditions:
- Ambient
- Storage Conditions:
- 4[o]C (Powder; sealed storage; away from moisture and light)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Membrane Transporter/Ion Channel;Neuronal Signaling
